Pathology
Peripheral blood findings at diagnosis
Pancytopenia: 50%
“Leukemic” phase with a WBC >1000/mm3: 10–20%
Monocytopenia
Hairy cells identified in most patients, but the number is usually low and may be difficult to identify in the peripheral blood because of low numbers and staining technique
Bone marrow findings at diagnosis
Hypercellularity
Hairy cell infiltration: diffuse, patchy, or interstitial
Diffuse infiltration: Often results in complete effacement of bone marrow
Patchy infiltration: Subtle small clusters of hairy cells present focally or throughout the bone marrow
Interstitial Infiltration: Hairy cells do not form well-defined discreet aggregates, but merge almost imperceptibly with surrounding normal hematopoietic tissue
Hairy cell nuclei are usually round, oval, or indented, and are widely separated from each other by abundant, clear or lightly eosinophilic cytoplasm. Rarely hairy cells can be convoluted or spindle shaped
Extravasated blood cells create blood lakes in the bone marrow similar to those observed in the spleen
Mast cells are often numerous
Reticulin stain of the bone marrow almost always shows moderate to marked increase in reticulin fibers
Approximately 10–20% of patients show a hypocellular bone marrow
Immunophenotyping, cytogenetics, and molecular diagnostic studies
Cytochemical studies: Tartrate-resistant acid phosphatase (TRAP) stain. However, TRAP is not specific for HCL
Hairy cell immunophenotype: CD19(+), CD20(+), CD22(+), CD79B(+), CD5(−), CD10(−), CD11C(+), CD25 Sub(+), FMC(+), CD103(+), CD45(+)
Clonal cytogenetics: Abnormalities in approximately two-thirds of patients. Chromosomes 1, 2, 5, 6, 11, 14, 19, and 20 are most frequently involved. Chromosome 5 is altered in approximately 40%, most commonly as a trisomy 5, pericentric inversion, and interstitial deletions involving band 5q13. However, the identification of cytogenetic abnormalities in a patient with a definite diagnosis of HCL is usually not important as it does not influence, as far as is currently determined, prognosis or therapy
Bartl R et al. Am J Clin Pathol 1983;79:531–545
Brunning RD et al. Atlas of Tumor Pathology, 3rd Series, Fascicle 9. Washington DC, AFIP, 1994; pp 277–278
Burke JS et al. Am J Clin Pathol 1978;70:876–884
Burke JS et al. Semin Oncol 1984;11:334–346
Cornfield DB et al. Am J Hematol 2001;67:223–226
Ellison DJ et al. Blood 1994;84:4310–4315
Flandrin G et al. Semin Oncol 1984;11(4 Suppl 2):458–471
Golomb HM et al. Ann Intern Med 1978;89(Part 1):677–683
Haglund U et al. Blood 1994;83:2637–2645
Hakimian D et al. Blood 1993;82:1798–1802
Hanson CA et al. Am J Surg Pathol 1989;13:671–679
Hounieu H et al. Am J Clin Pathol 1992;98:26–33
Katayama I. Hematol Oncol Clin North Am 1988;2:585–602
Kluin-Nelemans HC et al. Blood 1994;84:3134–3141
Kroft SH et al. Blood Rev 1995;9:234–250
Lee WM, Beckstead JH. Cancer 1982;50:2207–2210
Robbins BA et al. Blood 1993;82:1277–1287
Sausville JE ...